L’Oréal, according to a May 19, 2015 BBC (British Broadcasting Corporation) online news item, has partnered with Organovo, a 3D bioprinting startup, to begin producing skin,

French cosmetics firm L’Oreal is teaming up with bio-engineering start-up Organovo to 3D-print human skin.

It said the printed skin would be used in product tests.

Organovo has already made headlines with claims that it can 3D-print a human liver but this is its first tie-up with the cosmetics industry.

Experts said the science might be legitimate but questioned why a beauty firm would want to print skin. [emphasis mine]

L’Oreal currently grows skin samples from tissues donated by plastic surgery patients. It produces more than 100,000, 0.5 sq cm skin samples per year and grows nine varieties across all ages and ethnicities.

Its statement explaining the advantage of printing skin, offered little detail: “Our partnership will not only bring about new advanced in vitro methods for evaluating product safety and performance, but the potential for where this new field of technology and research can take us is boundless.”

The beauty and cosmetics industry has a major interest in technology, especially anything to do with the skin. I’m curious as to what kind of an expert wouldn’t realize that cosmetics companies test products on skin and might like to have a ready supply. Still, I have to admit to surprise when I first (2006) started researching nanotechnology;  L’Oréal at one point was the sixth largest nanotechnology patent holder in the US (see my Nanotech Mysteries Wiki page: Marketers put the buy in nano [scroll down to Penetration subhead]). In 2008 L’Oréal company representatives were set for a discussion on their nanotechnology efforts and the precautionary principle, which was to be hosted by the Wilson Center’s Project for Emerging Nanotechnologies (PEN). The company cancelled at a rather interesting time as I had noted in my June 19, 2008 posting. (scroll down about 40% of the way until you see mention of Dr. Andrew Maynard).

Back to 3D printing technology and cosmetics giants, a May 5, 2015 Organovo/L’Oréal press release provides more detail about the deal,

L’Oreal USA, the largest subsidiary of the world’s leading beauty company, has announced a partnership with 3-D bioprinting company Organovo Holdings, Inc. (NYSE MKT: ONVO) (“Organovo”).  Developed between L’Oreal’s U.S.-based global Technology Incubator and Organovo, the collaboration will leverage Organovo’s proprietary NovoGen Bioprinting Platform and L’Oreal’s expertise in skin engineering to develop 3-D printed skin tissue for product evaluation and other areas of advanced research.

This partnership marks the first-ever application of Organovo’s groundbreaking technology within the beauty industry.

“We developed our technology incubator to uncover disruptive innovations across industries that have the potential to transform the beauty business,” said Guive Balooch, Global Vice President of L’Oreal’s Technology Incubator.  “Organovo has broken new ground with 3-D bioprinting, an area that complements L’Oreal’s pioneering work in the research and application of reconstructed skin for the past 30 years. Our partnership will not only bring about new advanced in vitro methods for evaluating product safety and performance, but the potential for where this new field of technology and research can take us is boundless.”

Organovo’s 3D bioprinting enables the reproducible, automated creation of living human tissues that mimic the form and function of native tissues in the body.

“We are excited to be partnering with L’Oreal, whose leadership in the beauty industry is rooted in scientific innovation and a deep commitment to research and development,” said Keith Murphy, Chairman and Chief Executive Officer at Organovo. “This partnership is a great next step to expand the applications of Organovo’s 3-D bioprinting technology and to create value for both L’Oreal and Organovo by building new breakthroughs in skin modeling.”

I don’t have much information about Organovo here, certainly nothing about the supposed liver (how did I miss that?), but there is a Dec. 26, 2012 posting about its deal with software giant, Autodesk.